MX2022001967A - Composiciones de células t específicas para virus de terceros y métodos para prepararlas y usarlas en profilaxis antiviral. - Google Patents

Composiciones de células t específicas para virus de terceros y métodos para prepararlas y usarlas en profilaxis antiviral.

Info

Publication number
MX2022001967A
MX2022001967A MX2022001967A MX2022001967A MX2022001967A MX 2022001967 A MX2022001967 A MX 2022001967A MX 2022001967 A MX2022001967 A MX 2022001967A MX 2022001967 A MX2022001967 A MX 2022001967A MX 2022001967 A MX2022001967 A MX 2022001967A
Authority
MX
Mexico
Prior art keywords
methods
specific
subject
making
same
Prior art date
Application number
MX2022001967A
Other languages
English (en)
Inventor
Ann Marie Leen
Valdes Juan Fernando Vera
Ifigeneia Tzannou
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of MX2022001967A publication Critical patent/MX2022001967A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
    • A61K2239/30—Mixture of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación incluye composiciones y métodos para prevenir infección viral y/o prevenir la reactivación de un virus latente en un sujeto. Los métodos involucran administrar profilácticamente al menos una línea de células T específicas de antígeno de un donante de terceros y/o un mini-banco de donantes y/o un banco de donantes a un sujeto. El sujeto puede ser un paciente que ha recibido un trasplante (por ejemplo, un trasplante de tejido, órgano sólido o médula ósea) o quien tiene la necesidad de dicho trasplante, o está inmunocomprometido o tiene la necesidad de terapia inmunosupresora.
MX2022001967A 2019-08-16 2020-08-14 Composiciones de células t específicas para virus de terceros y métodos para prepararlas y usarlas en profilaxis antiviral. MX2022001967A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962887806P 2019-08-16 2019-08-16
PCT/US2020/046389 WO2021034674A1 (en) 2019-08-16 2020-08-14 Third party virus-specific t cell compositions, and methods of making and using the same in anti-viral prophylaxis

Publications (1)

Publication Number Publication Date
MX2022001967A true MX2022001967A (es) 2022-05-16

Family

ID=74659959

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001967A MX2022001967A (es) 2019-08-16 2020-08-14 Composiciones de células t específicas para virus de terceros y métodos para prepararlas y usarlas en profilaxis antiviral.

Country Status (11)

Country Link
US (1) US20220288119A1 (es)
EP (1) EP4013897A1 (es)
JP (1) JP2022545654A (es)
KR (1) KR20220048021A (es)
CN (1) CN114555836A (es)
AU (1) AU2020333654A1 (es)
BR (1) BR112022002827A2 (es)
CA (1) CA3151356A1 (es)
IL (1) IL290620A (es)
MX (1) MX2022001967A (es)
WO (1) WO2021034674A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
HRP20221303T1 (hr) 2012-02-09 2022-12-23 Baylor College Of Medicine SMJESE PEPTIDA ZA NASTAJANJE MULTIVIRUSNIH CITOTOKSIČNIH T-LIMFOCITA(CTLs) ŠIROKE SPECIFIČNOSTI
AU2013274416B2 (en) * 2012-06-11 2019-07-04 Wilson Wolf Manufacturing, LLC Improved methods of cell culture for adoptive cell therapy
WO2017049291A1 (en) 2015-09-18 2017-03-23 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
EP3974029A1 (en) * 2020-09-25 2022-03-30 Universidad Autónoma de Madrid Memory t cells as adoptive cell therapy for viral infections
EP4259163A2 (en) * 2020-12-09 2023-10-18 Tevogen Bio Inc. Virus specific t-cells and methods of treating and preventing viral infections
TW202340455A (zh) * 2021-11-23 2023-10-16 美國貝勒醫學院 改良之病毒特異性ｔ細胞

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2470644T3 (en) * 2009-08-24 2017-01-16 Baylor College Medicine GENERATION OF CTL LINES WITH SPECIFICITY AGAINST MORE TUMOR ANTIGEN OR MORE
HRP20221303T1 (hr) 2012-02-09 2022-12-23 Baylor College Of Medicine SMJESE PEPTIDA ZA NASTAJANJE MULTIVIRUSNIH CITOTOKSIČNIH T-LIMFOCITA(CTLs) ŠIROKE SPECIFIČNOSTI
WO2017049291A1 (en) 2015-09-18 2017-03-23 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy

Also Published As

Publication number Publication date
EP4013897A1 (en) 2022-06-22
AU2020333654A1 (en) 2022-03-17
WO2021034674A1 (en) 2021-02-25
BR112022002827A2 (pt) 2022-05-10
US20220288119A1 (en) 2022-09-15
CA3151356A1 (en) 2021-02-25
KR20220048021A (ko) 2022-04-19
CN114555836A (zh) 2022-05-27
JP2022545654A (ja) 2022-10-28
IL290620A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
MX2022001967A (es) Composiciones de células t específicas para virus de terceros y métodos para prepararlas y usarlas en profilaxis antiviral.
MX2020006864A (es) Modalidades combinadas para inhibidores de nucleosidos y/o nadph oxidasa (nox) como agentes antivirales especificos de mieloides.
Güell et al. PERV inactivation is necessary to guarantee absence of pig-to-patient PERVs transmission in xenotransplantation
ZA202107015B (en) Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
BR112021022458A2 (pt) Células pluripotentes modificadas ou uma célula derivada das mesmas, método de transplantar uma célula, método de tratamento de uma doença em um paciente em necessidade de células transplantadas, método para gerar uma célula pluripotente modificada, método para gerar uma célula hipoimunogênica pluripotente, e método de transplante de uma célula pluripotente hipoimunogênica (hip) ou célula derivada da mesma
MX2023001831A (es) Métodos de tratamiento de pacientes sensibilizados con células hipoinmunogénicas y métodos y composiciones asociados.
HK1071379A1 (en) Long lasting fusion peptide inhibitors for hiv infection
MX343505B (es) Metodos y composiciones para inhibir la transmision del vih.
MX2022010870A (es) Composicion que comprende lactoferrina y cepas bacterianas probioticas para uso oral con accion antiviral.
MX2021004593A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
CL2012002744A1 (es) Compuesto inhibidor no nucleosídico de la transcriptasa inversa derivado de 3-(hidrocarbiloxi aromático y alifático opcionalmente sustituido)-1-[(5-oxo-4,5-dihidro-1h-1,2,4-triazol-3-il)metil])-piridin-2(ih)-ona; composición farmacéutica que lo comprende útil en la profilaxis y tratamiento de la infección por vih y sida.
ATE503769T1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
PE20081215A1 (es) Identificacion y caracterizacion de variantes de replicon de vhc con menor susceptibilidad a vhc-796, y metodos relacionados
MX2021015448A (es) Células linfocíticas activadas y métodos para usarlas para tratar cáncer y afecciones infecciosas.
WO2020028719A3 (en) Compositions comprising herpes simplex virus-1 for use in methods of treating and preventing cancer
WO2009120339A3 (en) Vectors for delivering disease neutralizing agents
Ellerhoff et al. Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus
Shattock et al. AIDS models: microbicides could learn from vaccines
EA201290852A1 (ru) Комбинированная терапия, включающая антагонист ccr5, ингибитор протеазы вич-1 и фармакокинетический усилитель
Li et al. Corneal xenotransplantation from pig to rhesus monkey: no signs of transmission of endogenous porcine retroviruses
CR20230315A (es) Compuestos de piridotriazina sustituidos y usos de estos
WO2022092995A3 (ko) Rna 인터액톰 포획 프로토콜 및 이를 활용하여 발굴한 항바이러스용 조성물
Locatelli Towards a novel therapy against AIDS
Murugan et al. Prevalence of HIV-2 infection in south Tamil Nadu
RU2012147474A (ru) Пироксикам для профилактического и терапевтического лечения герпетических инфекций